{"protocolSection": {"identificationModule": {"nctId": "NCT02676843", "orgStudyIdInfo": {"id": "AAAP4551"}, "secondaryIdInfos": [{"id": "R01NS076837", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01NS076837"}], "organization": {"fullName": "Columbia University", "class": "OTHER"}, "briefTitle": "Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations", "officialTitle": "Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations"}, "statusModule": {"statusVerifiedDate": "2019-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-11-25", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-11-25", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-01-15", "studyFirstSubmitQcDate": "2016-02-04", "studyFirstPostDateStruct": {"date": "2016-02-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-11-18", "resultsFirstSubmitQcDate": "2019-11-18", "resultsFirstPostDateStruct": {"date": "2019-12-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-11-18", "lastUpdatePostDateStruct": {"date": "2019-12-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Edward D Huey, MD", "investigatorTitle": "Assistant Professor of Psychiatry and Neurology", "investigatorAffiliation": "Columbia University"}, "leadSponsor": {"name": "Columbia University", "class": "OTHER"}, "collaborators": [{"name": "National Institute of Neurological Disorders and Stroke (NINDS)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.", "detailedDescription": "Approximately 40% of cases of Frontotemporal lobar Degeneration (FTLD) are also associated with abnormal deposition of tau protein. The purpose of this study is to image MAPT mutation carriers and their non-carrier relatives in order to study the use of this tracer as a biomarker in Frontotemporal Lobar Degeneration with tau deposition (FTLD-tau)."}, "conditionsModule": {"conditions": ["Frontotemporal Lobar Degeneration (FTLD)", "Frontotemporal Dementia (FTD)", "Tauopathies"], "keywords": ["FTLD", "FTD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 7, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "18F-AV-1451", "type": "EXPERIMENTAL", "description": "Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.", "interventionNames": ["Drug: 18F-AV-1451"]}], "interventions": [{"type": "DRUG", "name": "18F-AV-1451", "description": "A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.", "armGroupLabels": ["18F-AV-1451"], "otherNames": ["[18F]AV-1451"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "SUVR of 18F-AV-1451", "description": "Regional tau deposition will be measured as standardized uptake value ratio (SUVR) of 18F-AV-1451. SUVR (80-100 min post-injection) for 18F-AV-1451 will be calculated two ways: 1) using cerebellar crus as a reference region, and 2) using the Parametric Estimation of Reference Signal Intensity (PERSI) method to create individual white matter reference regions. Binding in the inferior temporal lobe/cortex was used as the primary outcome.", "timeFrame": "Baseline, 12-month follow up"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Members of families with established MAPT mutations, who either have the capacity to consent to participate in the protocol, or else have designated a surrogate/proxy to consent to participate in this study\n\nExclusion Criteria:\n\n* Unwillingness to participate\n* Usage of medication which significantly prolongs QT interval\n* Pregnancy or plans for pregnancy within 90 days after participating in study", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Edward Huey, MD", "affiliation": "Columbia University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Morton A. Kreitchman PET Center", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "De-identified clinical characteristics subjects such as age, mutation and rating scale/score of mental state in the manuscript.", "timeFrame": "Availability of the manuscript through journal editors", "accessCriteria": "Availability of the manuscript through journal editors"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "18F-AV-1451", "description": "Subjects will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.\n\n18F-AV-1451: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "18F-AV-1451", "description": "Subjects will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.\n\n18F-AV-1451: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "7"}]}], "measures": [{"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "18-21 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "22-29 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "30-39 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "40-49 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}]}]}, {"title": "50-59 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}, {"title": "60-69 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "SUVR of 18F-AV-1451", "description": "Regional tau deposition will be measured as standardized uptake value ratio (SUVR) of 18F-AV-1451. SUVR (80-100 min post-injection) for 18F-AV-1451 will be calculated two ways: 1) using cerebellar crus as a reference region, and 2) using the Parametric Estimation of Reference Signal Intensity (PERSI) method to create individual white matter reference regions. Binding in the inferior temporal lobe/cortex was used as the primary outcome.", "populationDescription": "5 out of 7 subjects had data collected and analyzed (evaluable repeat imaging after 12 months).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "standardized uptake value ratio (SUVR)", "timeFrame": "Baseline, 12-month follow up", "groups": [{"id": "OG000", "title": "18F-AV-1451 - Non-carriers", "description": "Subjects who are microtubule associated protein tau (MAPT) family non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.\n\n18F-AV-1451: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan."}, {"id": "OG001", "title": "18F-AV-1451 - Carriers", "description": "Subjects who are MAPT family carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.\n\n18F-AV-1451: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"title": "Inferior temporal cortex (Cerebellar crus)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.07", "lowerLimit": "0.99", "upperLimit": "1.14"}, {"groupId": "OG001", "value": "1.26", "lowerLimit": "1.21", "upperLimit": "1.26"}]}]}, {"title": "Inferior temporal cortex (PERSI)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.03", "lowerLimit": "1.01", "upperLimit": "1.05"}, {"groupId": "OG001", "value": "1.34", "lowerLimit": "1.26", "upperLimit": "1.36"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 2 years", "eventGroups": [{"id": "EG000", "title": "18F-AV-1451", "description": "Subjects will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.\n\n18F-AV-1451: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.", "deathsNumAffected": 0, "deathsNumAtRisk": 7, "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 4, "otherNumAtRisk": 7}], "otherEvents": [{"term": "Insomnia", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 7}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 2, "numAtRisk": 7}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "William Kreisl, MD", "organization": "Columbia University", "email": "wck2107@cumc.columbia.edu", "phone": "212-342-2380"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2015-07-24", "uploadDate": "2019-11-06T11:31", "filename": "Prot_SAP_000.pdf", "size": 221798}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000057180", "term": "Frontotemporal Dementia"}, {"id": "D000018888", "term": "Aphasia, Primary Progressive"}, {"id": "D000020774", "term": "Pick Disease of the Brain"}, {"id": "D000024801", "term": "Tauopathies"}, {"id": "D000057174", "term": "Frontotemporal Lobar Degeneration"}], "ancestors": [{"id": "D000003704", "term": "Dementia"}, {"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000019965", "term": "Neurocognitive Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}, {"id": "D000057177", "term": "TDP-43 Proteinopathies"}, {"id": "D000019636", "term": "Neurodegenerative Diseases"}, {"id": "D000057165", "term": "Proteostasis Deficiencies"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000001037", "term": "Aphasia"}, {"id": "D000013064", "term": "Speech Disorders"}, {"id": "D000007806", "term": "Language Disorders"}, {"id": "D000003147", "term": "Communication Disorders"}, {"id": "D000019954", "term": "Neurobehavioral Manifestations"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M6904", "name": "Dementia", "relevance": "LOW"}, {"id": "M20929", "name": "Aphasia, Primary Progressive", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "M22530", "name": "Pick Disease of the Brain", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "M28762", "name": "Frontotemporal Dementia", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "M23002", "name": "Tauopathies", "asFound": "Tauopathies", "relevance": "HIGH"}, {"id": "M28756", "name": "Frontotemporal Lobar Degeneration", "asFound": "Frontotemporal Lobar Degeneration", "relevance": "HIGH"}, {"id": "M4352", "name": "Aphasia", "relevance": "LOW"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M21836", "name": "Neurocognitive Disorders", "relevance": "LOW"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M28759", "name": "TDP-43 Proteinopathies", "relevance": "LOW"}, {"id": "M21558", "name": "Neurodegenerative Diseases", "relevance": "LOW"}, {"id": "M28747", "name": "Proteostasis Deficiencies", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M15864", "name": "Speech Disorders", "relevance": "LOW"}, {"id": "M10823", "name": "Language Disorders", "relevance": "LOW"}, {"id": "M6374", "name": "Communication Disorders", "relevance": "LOW"}, {"id": "M21826", "name": "Neurobehavioral Manifestations", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}, {"id": "T2399", "name": "Frontotemporal Dementia", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "T2400", "name": "Frontotemporal Dementia, Ubiquitin-positive", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "T4710", "name": "Primary Progressive Aphasia", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "T5168", "name": "Semantic Dementia", "asFound": "Frontotemporal Dementia", "relevance": "HIGH"}, {"id": "T704", "name": "Behavioral Variant of Frontotemporal Dementia", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}